Compounded Ophthalmic Solution Recalled for Sterility Assurance Concerns
The Compounding Pharmacy of America is recalling Ascorbic Acid, Glutathione, and DMSO Ophthalmic Solution due to FDA inspection findings of GMP violations that impact sterility.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II. According to the rubric, an FDA Class II recall involving a sterile product with GMP violations impacting sterility is assigned a score of 4 (Severe), as it represents a significant risk of harm even without reported hospitalizations.
Plain-English summary
The Compounding Pharmacy of America is recalling Ascorbic Acid 1.25% Glutathione 1.25% DMSO 6.25% Ophthalmic Solution, Sterile, Refrigerate. The product is a 13 mL sterile ophthalmic solution distributed nationwide. The recall covers all lots distributed between November 2014 and May 2015, specifically lot 03032015@24 with an expiration date of 6/1/2015 and lot 03312015@79 with an expiration date of 6/29/2015.
The recall was initiated because an FDA inspection identified Good Manufacturing Practice (GMP) violations. These violations create a lack of assurance of sterility, potentially impacting the product's quality and safety. The source text does not report any specific illnesses or injuries associated with the use of this product.
Consumers and healthcare providers should stop using the recalled product and contact The Compounding Pharmacy of America for instructions on how to return or dispose of the medication. This recall is classified as FDA Class II, indicating a reasonable probability that use of the product may cause temporary or medically reversible adverse health consequences.
The recalled product
- Product
- Ascorbic Acid 1.25% Glutathione 1.25% DMSO 6.25% Ophthalmic Solution, Sterile, Refrigerate, The Compounding Pharmacy of America, Knoxville, TN
- Manufacturer
- The Compounding Pharmacy of America
- Category
- Drug — Compounded Ophthalmic
- Hazard
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (5)
- All lots distributed between November 2014 and May 2015
- 03032015@24
- 6/1/2015
- 03312015@79
- 6/29/2015
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 382 recalled by The Compounding Pharmacy of America under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 382 products in this recall →Related recalls
Same manufacturer · The Compounding Pharmacy of America
See all →- CriticalFDA Recalls Non-Sterile HCG and Methylcobalamin Injection Vials
FDA (Drugs) · 2018-02-21
- SevereFDA Recalls Morphine and Ropivacaine Compounded Solution Due to Sterility Concerns
FDA (Drugs) · 2015-09-23
- SevereHydromorphone Solution Recalled Due to Sterility Assurance Concerns
FDA (Drugs) · 2015-09-23
- SevereMorphine and Bupivacaine Solution Recalled for Sterility Concerns
FDA (Drugs) · 2015-09-23
- SevereMethylcobalamin Injectable Recalled for Sterility Assurance Concerns
FDA (Drugs) · 2015-09-23
Same hazard · sterility
See all →- HighFDA recalls injectable compounded mixture in single-use syringes
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Tirzepatide Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Semaglutide/Cyanocobalamin Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Tirzepatide/Cyanocobalamin Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereK.C. Pharmaceuticals Recalls Leader Advanced Relief Eye Drops for Sterility Concerns
FDA (Drugs) · 2026-10-14
Similar recalls
- SevereFDA Recalls Sterile Compounded Glutathione Products Due to Sterility Concerns
FDA (Drugs) · 2014-03-12
- SevereAscorbic/Glutathione Eye Solution Recalled for Sterility Concerns
FDA (Drugs) · 2021-11-03
- SevereRed Mountain Compounding Recalls S-Ascorbic/Glutathione Ophthalmic Solution
FDA (Drugs) · 2019-11-13
- SevereKey Pharmacy Recalls DMSO 6.25% Ophthalmic Solution Due to Sterility Concerns
FDA (Drugs) · 2017-05-24
- SevereNatures Pharmacy Recalls Sterile Compounded Products Due to Sterility Assurance Concerns
FDA (Drugs) · 2014-03-12
- SevereUS Compounding Recalls Acetylcysteine 10% Ophthalmic Solution for Sterility Concerns
FDA (Drugs) · 2015-11-25